NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Nurix Therapeutics, Inc.
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026
$24.93+0.51 (+2.09%)
Close on Oct 19, 2026
- Market cap
- $2.90B
- P/E (TTM)
- 10.8
- Dividend yield
- 0.00%
Nurix Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q4 23 | Q3 23 | Q2 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration revenue | $9.04M | $6.25M | $13.58M | $7.89M | $14.06M | $18.45M | $13.28M | $12.59M | $12.09M | $15.16M | $18.47M | $10.68M | 100.0% | -35.7% |
| License revenue | $0 | – | $0 | $0 | $30.00M | – | $0 | $0 | $0 | $0 | $0 | $20.00M | 0.0% | -100.0% |
By region
From the segment and revenue-disaggregation notes of Nurix Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.